Connection
Denise Damek to Glioblastoma
This is a "connection" page, showing publications Denise Damek has written about Glioblastoma.
|
|
Connection Strength |
|
|
|
|
|
1.170 |
|
|
|
-
Damek DM, Lillehei KO, Kleinschmidt-DeMasters BK. Aspergillus terreus brain abscess mimicking tumor progression in a patient with treated glioblastoma multiforme. Clin Neuropathol. 2008 Nov-Dec; 27(6):400-7.
Score: 0.268
-
Ung TH, Ney DE, Damek D, Rusthoven CG, Youssef AS, Lillehei KO, Ormond DR. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma. Neurosurgery. 2019 03 01; 84(3):687-695.
Score: 0.137
-
Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncol. 2017 01; 6(1):29-43.
Score: 0.116
-
Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015 Jun; 123(2):251-7.
Score: 0.105
-
Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol. 2015 Mar; 122(1):135-43.
Score: 0.103
-
Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, Ney D, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol. 2013 Aug; 114(1):111-6.
Score: 0.092
-
Khalil A, Serracino H, Damek DM, Ney D, Lillehei KO, Kleinschmidt-DeMasters BK. Genetic characterization of gliomas arising in patients with multiple sclerosis. J Neurooncol. 2012 Sep; 109(2):261-72.
Score: 0.085
-
Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):655-60.
Score: 0.085
-
Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1066-74.
Score: 0.077
-
Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):211-7.
Score: 0.076
-
Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Bar?n AE, Yeh N, Gaspar LE, Liu AK, Ney DE, Damek DM, Lillehei KO, Kavanagh BD. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):894-902.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|